Diphenhydramine Dosing Guidelines

Special Clinical Applications

For acute dystonic reactions, the dose is 1-2 mg/kg (maximum initial dose: 50 mg) IV/IM, which may cause sedation, respiratory suppression, hypotension, and paradoxical excitement, and rapid IV administration may precipitate seizures 1
For breakthrough antiemetic (chemotherapy-induced), the dose is 25-50 mg PO or IV every 4-6 hours as needed for dystonic reactions from other antiemetics, with an alternative of Benztropine 1-2 mg IV/IM if allergic to diphenhydramine 2

The American Academy of Sleep Medicine explicitly recommends against using diphenhydramine for sleep onset or sleep maintenance insomnia, with a mean sleep latency reduction of only 8 minutes versus placebo and total sleep time improvement of only 12 minutes versus placebo, and no improvement in quality of sleep compared to placebo 3, 4

Patients over 85 years should receive reduced doses due to increased anticholinergic sensitivity, with a higher risk of cognitive impairment, delirium, and falls, and consideration of alternative non-sedating antihistamines when sedation is a concern, and for insomnia in elderly, consideration of doxepin 3-6 mg instead 5

Anticholinergic side effects include confusion and delirium, especially in elderly, dry mouth, blurred vision, urinary retention, constipation, hypotension and tachycardia, and impaired psychomotor performance 5
Rapid IV administration increases the risk of adverse cardiovascular effects, including cardiac toxicity risk 1

Monitor for changes in mental status or excessive sedation, assess falls risk, especially in elderly, and watch for urinary retention and constipation 5

Diphenhydramine can cause a paradoxical reaction, resulting in acute dystonia, despite being a standard treatment for dystonic reactions from other medications, as noted by the National Comprehensive Cancer Network 6

The American Academy of Neurology and other medical societies imply that diphenhydramine itself can cause acute dystonia, which can develop after both short-term and long-term therapy, with standard therapeutic doses, although no specific guideline is provided in the article 6